Evolus to Participate in Three Upcoming Investor Conferences
NEWPORT BEACH, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in three upcoming virtual investor conferences.
| Event: | Wells Fargo 2020 Virtual Healthcare Conference |
| Format: | Virtual Fireside chat |
| Date: | Thursday, September 10, 2020 |
| Time: | 1:20 – 1:50pm ET |
| Event: | H.C. Wainwright 22nd Annual Global Investment Conference |
| Format: | Virtual Fireside chat |
| Date: | Tuesday, September 15, 2020 |
| Time: | 12:30 – 12:50pm ET |
| Event: | Cantor 2020 Virtual Global Healthcare Conference |
| Format: | Virtual Fireside chat |
| Date: | Thursday, September 17, 2020 |
| Time: | 11:20 – 11:50am ET |
An audio webcast of Evolus’ presentation will be available on the investor relations section of Evolus’ website at . Replays of the webcasts will be available for 90 days after the date of the presentation.
About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: .
Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Evolus, Inc. Contacts:
Investor Contact:
Ashwin Agarwal, Evolus, Inc.
Vice President, Finance, Investor Relations & Treasury
Tel:
Email:
Media Contact:
Crystal Muilenburg, Evolus, Inc.
Vice President, Corporate Communications & Public Relations
Tel:
Email:
